4-(4-isopropoxyphenyl)piperidine | 1004852-98-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-(4-isopropoxyphenyl)piperidine
• 英文别名: 4-(4-propan-2-yloxyphenyl)piperidine
• CAS: 1004852-98-5
• 化学式: C₁₄H₂₁NO
• mdl: MFCD11130295
• 分子量: 219.327
• InChiKey: WRIBASYEJZKIAK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.571
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(4-isopropoxyphenyl)piperidine 在 吡啶 、 硝酸 作用下， 以 二氯甲烷 、 乙酸酐 为溶剂， 反应 6.0h， 生成 2,2,2-trifluoro-1-(4-(4-isopropoxy-3-nitrophenyl)piperidin-1-yl)ethanone
  参考文献：
  名称：

  Design, syntheses, and characterization of pharmacophore based chemokine receptor CCR5 antagonists as anti prostate cancer agents

  摘要：

  Accumulating evidence has shown multiple roles that chemokine receptor CCR5 may play to promote the progression of several types of cancer. The mechanism of such promotion is believed to involve chronic inflammation that creates a microenvironment which enhances tumor survival. Therefore, blocking CCR5 function with an antagonist may provide a novel treatment of cancers such as prostate cancer. Currently, several CCR5 antagonists are available, but all have been optimized for their inhibitory activity on HIV-1 cellular membrane invasion process rather than inhibition on cytoplasmic signaling pathways. Thus, there is need to develop CCR5 antagonists focusing on blockage of CCR5 downstream signaling and inhibition of CCR5 related prostate cancer proliferation and progression. In this report, a pharmacophore analysis was conducted based on docking studies of several known CCR5 antagonists in a CCR5 homology model. A unique structural skeleton for CCR5 antagonist was constructed and functionalized, resulting in a new series of small molecules to be synthesized and characterized. A combination of CCR5 calcium flux inhibition, anti prostate cancer cell proliferation, basal cytotoxicity, and in vivo animal model studies were applied to screen the newly synthesized compounds. Results from this study provided a potential lead compound for future CCR5 antagonist development focusing on prostate cancer therapy. Published by Elsevier Masson SAS.

  DOI：

  10.1016/j.ejmech.2013.09.004
• 作为产物：
  描述：

  1-溴-4-异丙氧基苯 在 5%-palladium/activated carbon 、 氢气 、 碘 、 magnesium 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 20.0 ℃ 、393.01 kPa 条件下， 反应 28.83h， 生成 4-(4-isopropoxyphenyl)piperidine
  参考文献：
  名称：

  Design, syntheses, and characterization of pharmacophore based chemokine receptor CCR5 antagonists as anti prostate cancer agents

  摘要：

  Accumulating evidence has shown multiple roles that chemokine receptor CCR5 may play to promote the progression of several types of cancer. The mechanism of such promotion is believed to involve chronic inflammation that creates a microenvironment which enhances tumor survival. Therefore, blocking CCR5 function with an antagonist may provide a novel treatment of cancers such as prostate cancer. Currently, several CCR5 antagonists are available, but all have been optimized for their inhibitory activity on HIV-1 cellular membrane invasion process rather than inhibition on cytoplasmic signaling pathways. Thus, there is need to develop CCR5 antagonists focusing on blockage of CCR5 downstream signaling and inhibition of CCR5 related prostate cancer proliferation and progression. In this report, a pharmacophore analysis was conducted based on docking studies of several known CCR5 antagonists in a CCR5 homology model. A unique structural skeleton for CCR5 antagonist was constructed and functionalized, resulting in a new series of small molecules to be synthesized and characterized. A combination of CCR5 calcium flux inhibition, anti prostate cancer cell proliferation, basal cytotoxicity, and in vivo animal model studies were applied to screen the newly synthesized compounds. Results from this study provided a potential lead compound for future CCR5 antagonist development focusing on prostate cancer therapy. Published by Elsevier Masson SAS.

  DOI：

  10.1016/j.ejmech.2013.09.004

文献信息

• [EN] SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION<br/>[FR] AMINOQUINOLONES SUBSTITUÉES EN TANT QU'INHIBITEURS DE DGKALPHA POUR ACTIVATION IMMUNITAIRE
  申请人：BAYER AG

  公开号：WO2021105117A1

  公开（公告）日：2021-06-03

  The present invention covers aminoquinolone compounds of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8 and n are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase alpha regulated disorders, as a sole agent or in combination with other active ingredients.

  本发明涵盖了一般式(I)的氨基喹啉酮化合物，其中R1、R2、R3、R4、R5、R6、R7、R8和n如本文所定义，制备所述化合物的方法，用于制备所述化合物的中间化合物，包括所述化合物的药物组合物和组合物，以及利用所述化合物制造用于治疗和/或预防疾病的药物组合物，特别是二酰基甘油激酶α调节性疾病，作为唯一药剂或与其他活性成分组合使用。
• [EN] PIPERIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF<br/>[FR] DÉRIVÉS DE PIPÉRIDINE, LEURS COMPOSITIONS PHARMACEUTIQUES ET LEURS UTILISATIONS
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2013079668A1

  公开（公告）日：2013-06-06

  The invention relates to new piperidine derivatives of the formula (I) to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

  这项发明涉及到新的哌啶衍生物的公式（I），以及它们作为药物的用途，它们的治疗用途的方法，以及含有它们的药物组合物。
• New piperidine derivatives, pharmaceutical compositions and uses thereof
  申请人：ROTH Gerald Juergen

  公开号：US20130143876A1

  公开（公告）日：2013-06-06

  The invention relates to new piperidine derivatives of the formula I to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

  这项发明涉及新的哌啶衍生物的公式I，其用作药物，其治疗用途的方法以及含有它们的药物组合物。
• [EN] NEW PIPERIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF<br/>[FR] NOUVEAUX DÉRIVÉS DE LA PIPÉRIDINE, LEURS COMPOSITIONS PHARMACEUTIQUES ET LEURS UTILISATIONS
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2013092976A1

  公开（公告）日：2013-06-27

  The invention relates to new piperidine derivatives of the formula (I) to their use as medicaments, to methods for their therapeutic use as inhibitors of acetyl-CoA carboxylases and to pharmaceutical compositions containing them.

  该发明涉及新的哌啶衍生物（I）的公式，其用作药物，用作乙酰辅酶A羧化酶抑制剂的治疗用途的方法，以及含有它们的药物组合物。
• Piperidine Derivatives
  申请人：ROTH Gerald Juergen

  公开号：US20130165444A1

  公开（公告）日：2013-06-27

  Piperidine derivatives of which the following is exemplary and their use in the treatment of obesity, diabetes or dyslipidemia.

  哌啶衍生物及其在肥胖、糖尿病或血脂异常治疗中的用途。